International St. Mary’s Hospital and Miracell Sign Joint Stem Cell Research Agreement
Cooperation to Expand Clinical and Stem Cell Research and Development, and Invigorate the Medical and Biohealth Sectors
Catholic Kwandong University International St. Mary’s Hospital (President Kim Hyun-soo) announced on the 27th that it had signed a business agreement with Miracell (CEO Shin Hyun-soon) for joint stem cell clinical research.
The signing ceremony was attended by Father Kim Hyun-soo, President of International St. Mary’s Hospital; Professor Chae Dong-sik (Orthopedic Surgery), Director of the Cell Therapy Center;
Miracell CEO Shin Hyun-soon, and representatives from both institutions.
Under this agreement, International St. Mary’s Hospital will establish a cooperative relationship with Miracell to promote research and development to improve national health and advance future medical technologies. To this end, the two organizations agreed to closely collaborate on: ▲ joint clinical and stem cell research and development; ▲ research and development in future medical fields;
and ▲ the revitalization of the medical and biohealth sectors.
Father Kim Hyun-soo, Director of International St. Mary’s Hospital, said, “Contributing to the improvement of national health and welfare through cutting-edge medical care is a truly valuable endeavor.”
“I hope this collaboration will provide an opportunity to provide more effective treatment to patients.”
Meanwhile, Miracell is a stem cell company that conducts joint research and development with domestic and international medical institutions to specialize in safe stem cell treatments.